Sumary of Buy Ipca Laboratories; target of Rs 1030: Motilal Oswal:
- After 18% YoY decrease in incomes in FY22, we expect 11% incomes CAGR over FY22-24, led by 13%8%8% sales CAGR in DF, commodities formulations, and API, respectively.
- Currently, it is trading 35.31 proportion below its 52-week high and 7.65 proportion above its 52-week debased.
- At 16:01 hrs Ipca Laboratories was repeat at Rs 895.00, up Rs 5.85, or 0.66 proportion.
- Thereby, we arrive at a value target of INR1,030 on 12M forward basis.
Want to know more click here go to source.
